Group 1: Tangrenshen - The company sold 2.9452 million pigs from January to July 2025, with an expected annual output of 5-5.5 million pigs [1] - The "company + farmer" model accounted for 80.64% of the fat pig output, with the proportion of new Dan series breeding pigs increasing from 56% to 76% [1] - The production cost of piglets decreased by 41 yuan per head, while the fattening cost dropped to 12.71 yuan per kilogram as of June 2025 [1] - The company plans to increase investment in meat business in the second half of 2025, aiming to develop a high-end fresh meat brand and promote nationwide meat business [1] Group 2: Jibeier - The antidepressant JJH201501 has completed Phase III clinical enrollment, follow-up, and data analysis, with a summary report being drafted [2] - Phase II clinical trials showed significant efficacy and good safety for JJH201501, while JJH201601 has completed Phase I and is undergoing Phase IIa trials [2] - Sales revenue for Niquilol tablets reached 91.0388 million yuan in the first half of 2025, representing a year-on-year growth of 38.31% [2] - The company has established a deuterated technology platform to advance the development of multiple deuterated new drugs [2] - A cash dividend distribution plan has been set, proposing a payout of 2.60 yuan per 10 shares for the first half of 2025 [2] Group 3: Chengquan Capital - Chengquan Capital was established in July 2015 in Beijing with a registered capital of 500 million yuan [3] - The company was founded by Hu Jiguang, a prominent figure in the asset management industry with 28 years of experience in securities and futures investment [3] - The investment research team consists of members from leading securities firms and influential research institutions, known for their rich experience and strong risk control capabilities [3] - The company aims to achieve a win-win situation for clients, employees, and shareholders, aspiring to become a respected and influential investment institution in the domestic capital market [3]

Core Viewpoint - The report outlines the continuous supervision work conducted by Guojin Securities for Jiangsu Jibeier Pharmaceutical Co., Ltd, confirming that the company has adhered to relevant regulations and has not encountered any significant legal violations during the supervision period [1][2][3]. Continuous Supervision Work - Guojin Securities has established and effectively implemented a continuous supervision work plan for Jibeier, including signing a supervision agreement that clarifies the rights and obligations of both parties [1][2]. - The supervision includes regular communication, site inspections, and due diligence to understand Jibeier's business situation [1][2]. - Jibeier has not reported any legal violations or breaches of commitments during the supervision period [1][2]. Compliance and Governance - The company has adhered to laws, regulations, and business rules set by the Shanghai Stock Exchange, ensuring compliance by its board members and senior management [1][2]. - Jibeier has established effective internal control systems, including financial management and auditing procedures [1][2]. Financial Performance - For the first half of 2025, Jibeier reported a revenue of CNY 454.92 million, a 4.90% increase from the previous year [7]. - The total profit reached CNY 173.38 million, reflecting a 24.36% increase year-on-year [7]. - The net profit attributable to shareholders was CNY 149.32 million, up 22.38% compared to the same period last year [7]. Research and Development - Jibeier is actively advancing its research projects, with two innovative drugs currently in clinical trials [8]. - The company maintains a strong focus on developing drugs for major diseases, including depression and cancer, which are competitive fields in the pharmaceutical industry [8]. Risk Factors - The company faces risks related to core competitiveness, particularly concerning its main product, Likujun tablets, which could be affected by competition from generic drugs [5]. - Operational risks include potential quality issues during production and the impact of regulatory changes on drug pricing and market access [5][6]. - Financial risks are associated with the management of accounts receivable and the potential loss of tax benefits if the company fails to maintain its high-tech enterprise status [6][7]. Use of Raised Funds - As of June 30, 2025, Jibeier has effectively utilized the funds raised from its initial public offering, with a net amount of CNY 1.02 billion, of which CNY 903.41 million has been used [9][10]. - The company has complied with regulations regarding the management and use of raised funds, ensuring transparency and accountability [9][10].

Core Insights - The 2024 annual report performance briefing series for the biopharmaceutical industry on the Sci-Tech Innovation Board has commenced, focusing on new drug development, overseas business expansion, and future development strategies as key investor concerns [1] Group 1: New Drug Development - The company plans to increase its R&D investment, with a total of 70.41 million yuan in 2024, representing a year-on-year increase of 26.25%. The company is conducting Phase III clinical trials for its antidepressant JJH201501 and Phase IIa trials for its anti-tumor drug JJH201601 [2] - The company aims to complete the Phase III clinical research and new drug application for JJH201501 by the end of 2025, leveraging existing product channels for commercialization [2] - The company has established a professional R&D team of over 100 members and is focusing on innovative drug research, particularly first-class innovative drugs [2] Group 2: Future R&D Strategy - The company intends to enhance its R&D strategy by targeting major disease markets and utilizing a combination of in-house development, external collaborations, acquisitions, and product licensing to enrich its product pipeline [3] - The company is focusing on developing first-in-class antibody drugs, which carry high risks but could lead to revolutionary treatment breakthroughs [3] - The integration of artificial intelligence in drug development is seen as a new trend to improve efficiency and quality [4] Group 3: Overseas Business Expansion - The overseas business has become a focal point, with the company achieving good results in both domestic and international markets, particularly in the EU market for its albumin paclitaxel product [4] - The company plans to leverage its established overseas commercialization platform to introduce new products and drive sales, aiming for a 200% to 400% increase in overseas sales revenue by 2025 compared to 2023 [5] - The company will focus on high-tech barrier products in key markets and expedite the registration and market launch of introduced products [5] Group 4: Business Outlook - The company is committed to optimizing its product structure and enhancing operational efficiency while focusing on high-value-added product lines [6] - The company will continue to increase R&D investment and improve its management systems to ensure sustainable growth [6] - The company aims to implement an "AI + synthetic biology" strategy and pursue international development, leveraging digitalization and intelligence for high-quality, sustainable growth [7]